Filtered By:
Source: Thrombosis Research
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 221 results found since Jan 2013.
Increased circulating leukocyte-derived microparticles in ischemic cerebrovascular disease
In this study, we examined the hypothesis that the quantity of leukocyte-derived microparticles is increased in patients with ischemic cerebrovascular diseases, and investigated utility of various phenotypes of leukocyte-derived microparticles as specific biomarkers of vascular inflammation injury. Additionally we focused on identifying leukocyte-derived microparticles that may be correlated with stroke severity in acute ischemic stroke patients.
Source: Thrombosis Research - April 3, 2017 Category: Hematology Authors: Zhangping He, Yanyan Tang, Chao Qin Tags: Full Length Article Source Type: research
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation
Atrial fibrillation (AF) represents the most common arrhythmia in patients with chronic kidney disease (CKD). As in the general population, in CKD patients AF is associated with an increased risk of thromboembolism and stroke. However, CKD patients, especially those on renal replacement therapy (RRT), also exhibit an increased risk of bleeding, especially from the gastrointestinal tract.Oral anticoagulation is the most effective form of thromboprophylaxis in patients with AF presenting increased risk of stroke.
Source: Thrombosis Research - May 3, 2017 Category: Hematology Authors: L. Di Lullo, C. Ronco, M. Cozzolino, D. Russo, L. Russo, B. Di Iorio, A. De Pascalis, V. Barbera, M. Galliani, E. Vitaliano, C. Campana, F. Santoboni, A. Bellasi Tags: Review Article Source Type: research
Present status and future orientation of rivaroxaban application in patients with nonvulvular atrial fibrillation
Nonvalvular atrial fibrillation (NVAF) is one of the most common supraventricular arrhythmias that require anticoagulation therapy to prevent stroke and systemic embolism. It affects 2% of the European population and is associated with an approximate 5-fold increased stroke risk [1], while in China, the estimated age-standardized AF prevalence was 0.65% in 2008, suggesting that at least 4 million adults had AF [2], and it was predicted that 5.2 million men and 3.1 million women aged>60years will be affected by AF in China by 2050 [3].
Source: Thrombosis Research - May 17, 2017 Category: Hematology Authors: Sui Huang, Liang Tang, Yu Hu Tags: Editorial Source Type: research
CREM-transgene mice: A step towards understanding thrombogenesis in atrial fibrillation
Thrombo-embolic stroke is one of the most consequential complications of atrial fibrillation. One of the first decisions made when managing patients with this condition is estimating the thrombo-embolic risk and initiating appropriate therapy to lower this risk [1]. Several clinical risk factors have been associated with thrombo-embolization in atrial fibrillation, including age, hypertension, diabetes, heart failure, vascular disease and others. The predictive accuracy of clinical parameter based models for stroke prediction in AF has been modest [2], as the mechanistic explanation linking clinical risk factors to thrombu...
Source: Thrombosis Research - December 27, 2017 Category: Hematology Authors: Nazem Akoum Tags: Editorial Source Type: research
Can an anticoagulant reduce brain hemorrhage: Invited comment on “Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization”
During studies of anti-coagulants to prevent cardioembolic stroke, startling data emerged that patients treated with novel oral anti-coagulants (NOACs) appeared to suffer less brain hemorrhage than patients treated with traditional, vitamin-K depleting anticoagulants [1, 2]. That NOACs reduced the bleeding risk did not fit accepted dogma: clinicians imagine that hemorrhage occurs during and following ischemic stroke as the brain undergoes necrosis. In the presence of anti-coagulation, such necrotic bleeding ought to be augmented.
Source: Thrombosis Research - June 11, 2018 Category: Hematology Authors: Patrick D. Lyden Tags: Editorial Source Type: research
Recurrent venous thromboembolism after cerebral venous thrombosis: which lower-risk survivors are at risk for recurrence?
When speaking to young, high-functioning survivors of cerebral venous thrombosis (CVT) and other causes of stroke in the young, one common theme that emerges in follow-up is fear of recurrence. CVT is known to have an excellent functional prognosis in most, with 85 –90% achieving functional independence with the ability to carry out all previous activities [1,2]. However, as a rare cause of stroke in the young, an already rare event, CVT can be a traumatic and isolating experience, compounded by the aggravations of anticoagulation, and made worse by residual “invisible” deficits such as headache, fatigue, and neurops...
Source: Thrombosis Research - May 30, 2019 Category: Hematology Authors: Thalia S. Field Tags: Editorial Source Type: research
Quality of anticoagulation using intravenous unfractionated heparin for cerebrovascular indications
Urgent initiation of anticoagulation is frequently used in a subset of stroke patients, including those with intraluminal or cardiogenic emboli [1]. Traditionally, continuous unfractionated heparin (UFH) has been the anticoagulant of choice in this patient population due to its short half-life and reversal potential in the event of intracerebral hemorrhage. Our objective was to characterize the quality of anticoagulation in cerebrovascular conditions at a large comprehensive stroke centre.
Source: Thrombosis Research - January 6, 2021 Category: Hematology Authors: Tess Fitzpatrick, Courtney Wong, Cindy Shen, Peter Pham, Vincent Teo, Rita Selby, William Geerts, Houman Khosravani Tags: Letter to the Editors-in-Chief Source Type: research
Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research
Performance of four bleeding risk scores in patients with atrial fibrillation receiving antithrombotics
Atrial fibrillation (AF) confers the major risk for ischemic stroke and systemic embolism [1]. Although anticoagulants can reduce the risk of AF-associated stroke, thromboembolic events, and mortality [2,3], a major drawback is the increased the risk of bleeding [4,5]. The overall risks and benefits must be carefully considered when selecting the most appropriate antithrombotic therapy, and for this reason, accurate bleeding risk stratification is needed. In clinical practice, various bleeding risk scores have been proposed and validated to assess the risk of bleeding in AF patients receiving oral anticoagulants (OAC).
Source: Thrombosis Research - November 8, 2021 Category: Hematology Authors: Sun Young Choi, Moo Hyun Kim, Sung-Cheol Yun Tags: Letter to the Editors-in-Chief Source Type: research
Electronic alerts for ambulatory patients with atrial fibrillation not prescribed anticoagulation: A randomized, controlled trial (AF-ALERT2)
Despite widely available risk stratification tools, safe and effective anticoagulants, and guideline recommendations, anticoagulation for stroke prevention in atrial fibrillation (AF) is under-prescribed in ambulatory patients. To assess the impact of alert-based computerized decision support (CDS) on anticoagulation prescription in ambulatory patients with AF and high-risk for stroke, we conducted this randomized controlled trial.
Source: Thrombosis Research - May 10, 2023 Category: Hematology Authors: Gregory Piazza, Shelley Hurwitz, Umberto Campia, Behnood Bikdeli, Junyang Lou, Candrika D. Khairani, Antoine Bejjani, Julia E. Snyder, Mariana Pfeferman, Briana Barns, Samantha Rizzo, Alexandra Glezer, Samuel Z. Goldhaber Tags: Full Length Article Source Type: research
A low-volume, single pass in-vitro system of high shear thrombosis in a stenosis
Conclusions: Occlusive thrombus blocks the collagen-coated lumen with millions of platelets using human whole, heparinized blood. Rapid Platelet Accumulation rates in human blood are 4.5±2.4μm3/μm2/min (n=21). There is an initial lag time of 7.4±3.8min (n=21) before the onset of large scale thrombosis. The rates of platelet accumulation in vitro are consistent with the clinical timescale of coronary or carotid artery occlusion. Porcine blood has a faster accumulation rate of 9.6±6.1μm3/μm2/min (n=7, p
Source: Thrombosis Research - March 27, 2013 Category: Hematology Authors: Andrea N. Para, David N. Ku Tags: Coagulation and Fibrinolysis Source Type: research
Allogeneic bone marrow mesenchymal stem cells transplantation for stabilizing and repairing of atherosclerotic ruptured plaque
Abstract: Introduction: There have been no satisfactory therapies on stabilizing and repairing ruptured plagues nowadays, which are the fundamental causes of acute coronary syndrome (ACS) and stroke. The aim of this study was to investigate the therapeutic potential of bone marrow mesenchymal stem cells (MSCs) in stabilizing and repairing ruptured plaques.Materials and Methods: 28 male New Zealand rabbits were randomly divided into 2 groups after establishment of atherosclerotic disrupted plaque model by liquid nitrogen frostbite: MSCs transplantation group and control group. MSCs were isolated, cultured in vitro, and labe...
Source: Thrombosis Research - April 25, 2013 Category: Hematology Authors: Shun-Miao Fang, Da-Yong Du, Yun-Tian Li, Xing-Li Ge, Peng-Tao Qin, Qing-Hua Zhang, Yang Liu Tags: Platelets and Cell Biology Source Type: research
Time trends in pulmonary embolism: A matter of age and gender
Venous thromboembolism (VTE) is the third most common cardiovascular disease . Pulmonary embolism (PE) is potentially lethal and is the most serious manifestation of VTE . Notably, PE is the leading preventable cause of death in hospitalized patients , and is the third most common cardiovascular cause of death after myocardial infarction and stroke in Western world . Risk factors for VTE and PE include old age, surgery, immobilization, trauma, fractures, cancer, pregnancy, puerperium, oral contraceptive pill (OCP) use, and hormone replacement therapy (HRT) . Genetic factors are also important in VTE risk and family history...
Source: Thrombosis Research - June 24, 2013 Category: Hematology Authors: Bengt Zöller Tags: Editorials Source Type: research
The Clinical Implications of ADAMTS13 Function: The Perspectives of Haemostaseologists
This article reviews the literature in these conditions.
Source: Thrombosis Research - September 19, 2013 Category: Hematology Authors: Savita Rangarajan, Craig Kessler, Louis Aledort Tags: Mini-Reviews Source Type: research
Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease
Abstract: In adult patients with sickle cell disease two distinct subphenotypes have previously been defined: patients with the viscosity-vaso-occlusion subphenotype (VVO) suffer mainly from vaso-occlusive pain crises and have a relatively high hemoglobin concentration. Patients classified as the hemolysis-endothelial dysfunction subphenotype (HED) suffer from stroke and pulmonary hypertension and have an elevated concentration of lactate dehydrogenase. However, this classification is not possible in children due to low rates of complications. We used laboratory markers to classify children into the two subphenotypes, and ...
Source: Thrombosis Research - October 31, 2013 Category: Hematology Authors: Veronica van der Land, Marjolein Peters, Bart J. Biemond, Harriët Heijboer, Cornelis L. Harteveld, Karin Fijnvandraat Tags: Platelets and Cell Biology Source Type: research
